156 related articles for article (PubMed ID: 38580937)
21. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
22. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
23. Radiation therapy in small cell lung cancer: a national Italian survey.
Ciammella P; Timon G; Bruni A; Franceschini D; Borghetti P; Giaj-Levra N; Greco C; Scotti V; Trovo M;
Radiol Med; 2018 Jul; 123(7):554-560. PubMed ID: 29536412
[TBL] [Abstract][Full Text] [Related]
24. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
[TBL] [Abstract][Full Text] [Related]
25. Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): a population based outcome study.
Soon YY; Zheng H; Ho SZ; Koh WY; Leong CN; Tey JCS; Vellayappan B; Yap SP; Tham IWK; Fong KW
Radiat Oncol; 2018 Dec; 13(1):247. PubMed ID: 30547818
[TBL] [Abstract][Full Text] [Related]
26. Current Patterns of Care for Patients with Extensive-Stage SCLC: Survey of U.S. Radiation Oncologists on Their Recommendations Regarding Prophylactic Cranial Irradiation.
Jain A; Luo J; Chen Y; Henderson MA; Thomas CR; Mitin T
J Thorac Oncol; 2016 Aug; 11(8):1305-1310. PubMed ID: 27237826
[TBL] [Abstract][Full Text] [Related]
27. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Agarwal M; Liu A; Langlais BT; Leventakos K; Yu NY; Almquist D; Manochakian R; Ernani V
Clin Lung Cancer; 2023 Nov; 24(7):591-597. PubMed ID: 37365076
[TBL] [Abstract][Full Text] [Related]
28. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.
Demedts IK; Vermaelen KY; van Meerbeeck JP
Eur Respir J; 2010 Jan; 35(1):202-15. PubMed ID: 20044461
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients.
Ma X; Zhang Z; Chen X; Zhang J; Nie J; Da L; Hu W; Tian G; Wu D; Han J; Han S; Long J; Wang Y; Fang J
Thorac Cancer; 2021 Jun; 12(12):1841-1850. PubMed ID: 33955685
[TBL] [Abstract][Full Text] [Related]
30. The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.
Kesarwala AH; Lu DJ; Xanthopoulos E; Apisarnthanarax S; Cengel KA; Evans TL; Aggarwal C; Cohen RB; Langer CJ; Rengan R; Simone CB
Clin Lung Cancer; 2018 Mar; 19(2):e205-e209. PubMed ID: 29153967
[TBL] [Abstract][Full Text] [Related]
31. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
[TBL] [Abstract][Full Text] [Related]
32. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
Hatfield LA; Huskamp HA; Lamont EB
J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
[TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
[TBL] [Abstract][Full Text] [Related]
34. Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):658-666. PubMed ID: 30007803
[TBL] [Abstract][Full Text] [Related]
35. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
Shao C; He J; Kachroo S; Jin F
Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H; Azuma K; Shimose T; Yoshioka H; Kurata T; Shingu N; Okamoto M; Kawashima Y; Okamoto I
Thorac Cancer; 2023 Jan; 14(1):105-107. PubMed ID: 36380738
[TBL] [Abstract][Full Text] [Related]
38. Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.
Sun A; Abdulkarim B; Blais N; Greenland J; Louie AV; Melosky B; Schellenberg D; Snow S; Liu G
Lung Cancer; 2023 May; 179():107166. PubMed ID: 36944282
[TBL] [Abstract][Full Text] [Related]
39. Management of small-cell lung cancer: incremental changes but hope for the future.
Hann CL; Rudin CM
Oncology (Williston Park); 2008 Nov; 22(13):1486-92. PubMed ID: 19133604
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
